Analyst Expectations for Pacific Biosciences's Future
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has received mixed analyst ratings in the last quarter, with 2 bullish, 2 somewhat bullish, and 5 indifferent ratings. The average 12-month price target from 9 analysts is $10.78, which is an 18.89% decrease from the previous target of $13.29. Analysts consider company financials, conference calls, and insider communications to provide these ratings, which are updated quarterly or after major company events.
December 13, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pacific Biosciences has a mixed outlook from analysts with an average price target of $10.78, indicating a potential downside based on the current target compared to the previous one.
The average price target for Pacific Biosciences has been lowered, which typically suggests that analysts expect the stock to perform worse in the future compared to previous expectations. This negative revision in the price target can lead to a decrease in investor confidence and potentially a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100